Treatment response data for 10 SMCD-eos patients and 1 UMPD patient (M/45) with the CHIC2 deletion/translocation
. | Patient 1 . | Patient 2 . | Patient 3 . | Patient 4 . | Patient 5 . | Patient 6 . | Patient 7 . | Patient 8 . | Patient 9 . | Patient 10 . | Patient 11 . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, y | 46 | 30 | 26 | 45 | 72 | 49 | 51 | 50 | 40 | 40 | 26 |
| Diagnosis date | 5/31/2001 | 6/12/2001 | 1/6/1994 | 4/29/02 | 2/29/2003 | 10/6/2003 | 8/5/2003 | 1/18/1995 | 10/1/1994 | 5/6/1992 | 4/10/2003 |
| Treatment date | 5/28/2002 | 8/13/2001 | 1/20/1994 | 5/2/2002 | 3/4/2003 | 10/15/2003 | 8/12/2003 | 6/1/2001 | 12/2/1997 | 4/20/1994 | 5/5/2003 |
| Follow-up, mo | 18+ | 28+ | 118+ | 17+ | 9+ | 5+ | 4+ | 30+ | 72+ | 115+ | 7+ |
| Current status | Alive | Alive | Alive | Alive | Alive | Alive | Alive | Alive | Alive | Dead | Alive |
| Prior treatment | None | HU, IFN | None | None | HU | Pred | HU, Pred | Pred, HU, IFN | Pred, HU, CsA, IFN | None | None |
| Imatinib mesylate induction/maintenance, mg/d or mg/BIW | 100/100 | 100/100 | NA | 100/100 | 100/100 | 100/100 | 100/100 | 100/100 | NA | NA | 100/100 |
| Other induction treatment | NA | NA | IFN 9MU TIW none | NA | NA | NA | NA | NA | 2-CdA (0.09 mg/kg/d × 7d/cycle) | IFN 5MU TIW + Pred 60mg/kg/d IFN 2MU TIW | NA |
| Treatment response | CR | CR | CR | CR | CR | CR | CR | CR | PR | CR | CR |
| Therapy status | |||||||||||
| Hgb level, g/dL | |||||||||||
| Before | 12.1 | 9.2 | 14.6 | 7.7 | 13.9 | 14 | 14.4 | 11.0 | 11.1 | 12.7 | 11.6 |
| After | 15.1 | 15.3 | 15.7 | 16.5 | 15.3 | 15.2 | 14.7 | 13.9 | 11.6 | 13.8 | 14.2 |
| WBC count, × 109/L | |||||||||||
| Before | 14.5 | 69.8 | 12.2 | 14.3 | 15.2 | 24.1 | 7.2 | 18.3 | 94.1 | 38.8 | 18.7 |
| After | 4.9 | 6.1 | 7.0 | 6.9 | 6.6 | 6.3 | 6.6 | 7.3 | 9.4 | 4.0 | 6.6 |
| AEC count, × 109/L | |||||||||||
| Before | 10.7 | 16.1 | 4.6 | 2.2 | 10.2 | 12.2 | 2.1 | 15.0 | 81.9 | 14.0 | 10.1 |
| After | 0.2 | 0.3 | 0.7 | 0.3 | 0.4 | 0.3 | 0.3 | 0.1 | 4.2 | 0.3 | 0.1 |
| Platelet count, × 109/L | |||||||||||
| Before | 118 | 31 | 178 | 53 | 213 | 206 | 143 | 135 | 112 | 81 | 151 |
| After | 169 | 179 | 134 | 117 | 227 | 271 | 171 | 245 | 141 | 132 | 232 |
| CHIC2 deletion, % abnormal nuclei | |||||||||||
| Before | 61.0 | 58.0 | 47.0 | 87.5 | 76.0 | 45 | 48.0 | 42.0 | 64.0 | 80.0 | 74.0 |
| After | 0.0 | 1.5 | ND | 1 | 0.5 | 1 | ND | ND | ND | ND | ND |
. | Patient 1 . | Patient 2 . | Patient 3 . | Patient 4 . | Patient 5 . | Patient 6 . | Patient 7 . | Patient 8 . | Patient 9 . | Patient 10 . | Patient 11 . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, y | 46 | 30 | 26 | 45 | 72 | 49 | 51 | 50 | 40 | 40 | 26 |
| Diagnosis date | 5/31/2001 | 6/12/2001 | 1/6/1994 | 4/29/02 | 2/29/2003 | 10/6/2003 | 8/5/2003 | 1/18/1995 | 10/1/1994 | 5/6/1992 | 4/10/2003 |
| Treatment date | 5/28/2002 | 8/13/2001 | 1/20/1994 | 5/2/2002 | 3/4/2003 | 10/15/2003 | 8/12/2003 | 6/1/2001 | 12/2/1997 | 4/20/1994 | 5/5/2003 |
| Follow-up, mo | 18+ | 28+ | 118+ | 17+ | 9+ | 5+ | 4+ | 30+ | 72+ | 115+ | 7+ |
| Current status | Alive | Alive | Alive | Alive | Alive | Alive | Alive | Alive | Alive | Dead | Alive |
| Prior treatment | None | HU, IFN | None | None | HU | Pred | HU, Pred | Pred, HU, IFN | Pred, HU, CsA, IFN | None | None |
| Imatinib mesylate induction/maintenance, mg/d or mg/BIW | 100/100 | 100/100 | NA | 100/100 | 100/100 | 100/100 | 100/100 | 100/100 | NA | NA | 100/100 |
| Other induction treatment | NA | NA | IFN 9MU TIW none | NA | NA | NA | NA | NA | 2-CdA (0.09 mg/kg/d × 7d/cycle) | IFN 5MU TIW + Pred 60mg/kg/d IFN 2MU TIW | NA |
| Treatment response | CR | CR | CR | CR | CR | CR | CR | CR | PR | CR | CR |
| Therapy status | |||||||||||
| Hgb level, g/dL | |||||||||||
| Before | 12.1 | 9.2 | 14.6 | 7.7 | 13.9 | 14 | 14.4 | 11.0 | 11.1 | 12.7 | 11.6 |
| After | 15.1 | 15.3 | 15.7 | 16.5 | 15.3 | 15.2 | 14.7 | 13.9 | 11.6 | 13.8 | 14.2 |
| WBC count, × 109/L | |||||||||||
| Before | 14.5 | 69.8 | 12.2 | 14.3 | 15.2 | 24.1 | 7.2 | 18.3 | 94.1 | 38.8 | 18.7 |
| After | 4.9 | 6.1 | 7.0 | 6.9 | 6.6 | 6.3 | 6.6 | 7.3 | 9.4 | 4.0 | 6.6 |
| AEC count, × 109/L | |||||||||||
| Before | 10.7 | 16.1 | 4.6 | 2.2 | 10.2 | 12.2 | 2.1 | 15.0 | 81.9 | 14.0 | 10.1 |
| After | 0.2 | 0.3 | 0.7 | 0.3 | 0.4 | 0.3 | 0.3 | 0.1 | 4.2 | 0.3 | 0.1 |
| Platelet count, × 109/L | |||||||||||
| Before | 118 | 31 | 178 | 53 | 213 | 206 | 143 | 135 | 112 | 81 | 151 |
| After | 169 | 179 | 134 | 117 | 227 | 271 | 171 | 245 | 141 | 132 | 232 |
| CHIC2 deletion, % abnormal nuclei | |||||||||||
| Before | 61.0 | 58.0 | 47.0 | 87.5 | 76.0 | 45 | 48.0 | 42.0 | 64.0 | 80.0 | 74.0 |
| After | 0.0 | 1.5 | ND | 1 | 0.5 | 1 | ND | ND | ND | ND | ND |
All patients are male.
HU indicates hydroxyurea; IFN, interferon; Pred, prednisone; CsA, cyclosporine A; BIW, twice a week; d, day; NA, not applicable; MU, million units; TIW, thrice a week; 2-CdA, 2-chlorodeoxyadenosine; CR, complete response; PR, partial response; Hgb, hemoglobin; WBC, white blood cell count; AEC, absolute eosinophil count; and ND, not done.